Sign In
Buy OCGN
$1.21
-0.0100 (-0.82%)
At Close: Jun 12, 2026
Ocugen to Host Conference Call on Tuesday, May 5 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2026 Financial Results
07:02am, Wednesday, 29'th Apr 2026
MALVERN, Pa., April 29, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that i
Ocugen to Present at April 2026 Investor and Industry Conferences
07:02am, Thursday, 23'rd Apr 2026
MALVERN, Pa., April 23, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that D
OCGN's Gene-Agnostic Strategy Could Reset Retinal Therapy
01:36pm, Wednesday, 22'nd Apr 2026
Ocugen's gene-agnostic therapy strategy targets broad retinal patient groups with one-time treatments, setting up major 2026-27 catalyst events.
Ocugen Stock Outlook: Valuation, Cash Runway and Dilution Risk
01:36pm, Wednesday, 22'nd Apr 2026
Ocugen offers upside from a packed 2026 catalyst calendar, but cash runway limits and dilution risk keep the pre-commercial biotech outlook finely balanced.
OCGN Gene Therapy Pipeline: Key 2026-27 Catalysts Ahead
01:36pm, Wednesday, 22'nd Apr 2026
Ocugen faces a packed 2026-27 catalyst window with filings, interim data and Phase III readouts across three one-time retinal gene therapies.
Ocugen, Inc. (NASDAQ:OCGN) Given Average Rating of “Moderate Buy” by Analysts
04:14am, Saturday, 11'th Apr 2026
Shares of Ocugen, Inc. (NASDAQ: OCGN - Get Free Report) have received an average rating of "Moderate Buy" from the five ratings firms that are covering the company, Marketbeat Ratings reports. One ana
AVAI, LCTX, OCGN, VRTX, and LGVN Advance Cell-Based and Gene-Therapy Approaches to Age-Related Disease Issued on behalf of Avaí Bio, Inc. Companies mentioned
Ocugen (OCGN) Up 2.9% Since Last Earnings Report: Can It Continue?
12:31pm, Friday, 03'rd Apr 2026
Ocugen (OCGN) reported earnings 30 days ago. What's next for the stock?
OCGN Completes Early Enrollment in Pivotal Stargardt Disease Study
11:15am, Thursday, 02'nd Apr 2026
Ocugen completes GARDian3 enrollment early as OCU410ST gene therapy targets Stargardt disease with no approved treatments. Data readouts are expected in Q3.
Ocugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of OCU410ST for Stargardt Disease
07:02am, Wednesday, 01'st Apr 2026
MALVERN, Pa., April 01, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that d
Ocugen Falls as Gene Therapy for Eye Disease Lags in Phase II Study
01:15pm, Wednesday, 25'th Mar 2026
OCGN stock falls after phase II data for OCU410 show lower lesion reduction than earlier results, despite 31% improvement in the eye disease study.
Ocugen, Inc. (OCGN) Discusses Top Line Results From Phase II ArMaDa Trial of OCU410 in Geographic Atrophy Transcript
05:54pm, Tuesday, 24'th Mar 2026
Ocugen, Inc. (OCGN) Discusses Top Line Results From Phase II ArMaDa Trial of OCU410 in Geographic Atrophy Transcript
Ocugen Eye Disease Gene Therapy Data Trails Earlier Results, Stocks Falls
10:40am, Tuesday, 24'th Mar 2026
OCU410 is an investigational gene therapy for geographic atrophy (GA) secondary to dry age-related macular degeneration (dAMD).
MALVERN, Pa., March 24, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced positi
MALVERN, Pa., March 23, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today anno
